Amalgamated Bank Lowers Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Amalgamated Bank reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report) by 7.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,577 shares of the company’s stock after selling 735 shares during the period. Amalgamated Bank’s holdings in Intellia Therapeutics were worth $262,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in NTLA. Los Angeles Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 3.7% in the 4th quarter. Los Angeles Capital Management LLC now owns 11,695 shares of the company’s stock valued at $357,000 after buying an additional 422 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Intellia Therapeutics by 7.3% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,651 shares of the company’s stock valued at $210,000 after acquiring an additional 451 shares during the period. Victory Capital Management Inc. boosted its position in shares of Intellia Therapeutics by 1.8% during the 3rd quarter. Victory Capital Management Inc. now owns 27,316 shares of the company’s stock worth $864,000 after purchasing an additional 470 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Intellia Therapeutics by 7.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 8,144 shares of the company’s stock worth $248,000 after purchasing an additional 582 shares during the period. Finally, Interchange Capital Partners LLC increased its holdings in shares of Intellia Therapeutics by 6.3% in the 4th quarter. Interchange Capital Partners LLC now owns 10,239 shares of the company’s stock valued at $311,000 after purchasing an additional 605 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.00% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $25.71 on Wednesday. The company has a 50-day simple moving average of $24.80 and a 200-day simple moving average of $27.26. The company has a market cap of $2.48 billion, a PE ratio of -4.80 and a beta of 1.85. Intellia Therapeutics, Inc. has a 12 month low of $19.37 and a 12 month high of $47.48.

Intellia Therapeutics (NASDAQ:NTLAGet Free Report) last released its earnings results on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. The firm had revenue of ($1.92) million during the quarter, compared to analysts’ expectations of $15.10 million. During the same period in the previous year, the company earned ($1.40) EPS. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Analyst Ratings Changes

NTLA has been the topic of a number of research analyst reports. BMO Capital Markets boosted their price objective on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Citigroup lowered their price target on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Friday, May 10th. Wolfe Research started coverage on Intellia Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Wedbush reissued a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. Finally, The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $136.00 to $32.00 in a research report on Friday, February 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $66.77.

View Our Latest Research Report on NTLA

Intellia Therapeutics Company Profile

(Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Read More

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.